Open AccessLaboratory parameters of hemostasis in patients with COVID-19
Author(s) -
Е. А. Серегина,
E. M. Koltsova,
Ф. И. Атауллаханов,
A. G. Rumyantsev
Publication year - 2021
Publication title -
voprosy gematologii/onkologii i immunopatologii v pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 3
eISSN - 2414-9314
pISSN - 1726-1708
DOI - 10.24287/1726-1708-2021-20-3-147-155
Subject(s) - coagulopathy , medicine , covid-19 , hemostasis , intensive care medicine , disease , infectious disease (medical specialty) , virology , outbreak
The new coronavirus infection (currently classified as COVID-19), first identified in December 2019 in Wuhan, China, has contributed to a significant increase in global mortality. Coagulopathy is a common disorder in COVID-19 patients, which develops in parallel with respiratory failure. Currently, COVID-19 continues to be a life-threatening disease and requires new developments and solutions to define preventive and curative strategies. Studies often report an abnormality in the balance of coagulation and fibrinolytic systems in COVID-19, but there is still no adequate set of laboratory tests that could provide a diagnosis of coagulopathy in COVID-19. This review analyzes current studies on the clinical manifestations of COVID-19 coagulopathy, and also analyzes the informativeness of laboratory hemostasis tests in relation to the severity of the disease and clinical outcomes.